Connected health company ResMed has announced it will pay $225 million to acquire inhaler monitoring company Propeller Health. ResMed has previously focused primarily on products for sleep apnea, including continuous positive airway pressure (CPAP) machines, as well as non-invasive ventilation (NIV) devices that can be used by COPD patients. Propeller health will remain a standalone company, and Co-Founder David Van Sickle will remain as CEO.
ResMed CEO Mick Farrell said, “Acquiring Propeller is a significant step for ResMed toward becoming the global leader in digital health for COPD. By working with Propeller’s existing partners to offer digital solutions for respiratory care pharmaceuticals and building on our proven ability to support digital solutions at scale, we can positively impact the lives of even more of the 380 million people worldwide who are living with this debilitating chronic disease.”
Propeller has partnered with numerous pharmaceutical, device, and healthcare companies for the use of its inhaler sensors and monitoring platform. Earlier this year, the company announced a funding round Aptar Pharma that includes a $10 million from Aptar Pharma, which had previously announced that it would co-develop a connected MDI with Propeller. Other companies that have partnered with Propeller over the past few years include US pharmacy benefits manager Express Scripts, GSK, Novartis, Vectura, and Boehringer Ingelheim.
Van Sickle commented, “ResMed shares our belief that connected health solutions create vastly better experiences and outcomes for people with chronic respiratory disease. Joining forces enables us to accelerate the adoption of Propeller’s solutions at a global scale, and serve as a powerful platform for a broad set of pharmaceutical and healthcare partners.”
Read the ResMed and Propeller Health press release.
